Skip to main content

Table 1 Patient Characteristics

From: XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy

  XM02
(n = 140)
Neupogen™
(n = 136)
Placebo/XM02*
(n = 72)
Gender [N (%)]    
Male 1 (0.7%) 1 (0.7%) -
Female 139 (99.3%) 135 (99.3%) 72 (100.0%)
Age [years]    
Mean 51.0 51.4 49.5
SD 9.7 10.7 10.3
Median 51.0 51.0 48.0
Range 25–75 28–74 28–74
Race [N (%)]    
Caucasian 120 (85.7%) 118 (86.8%) 62 (86.1%)
Black 1 (0.7%) 5 (3.7%) 2 (2.8%)
Hispanic 10 (7.1%) 10 (7.4%) 6 (8.3%)
Other 9 (6.4%) 3 (2.2%) 2 (2.8%)
Body Mass Index [kg/m 2 ]    
Mean 27.77 28.20 27.42
SD 6.11 5.70 6.02
Median 27.55 26.90 27.30
Range 16.2–56.2 15.9–45.4 17.0–41.3
Cancer stage [N (%)]    
High risk stage II 23 (16.4%) 36 (26.5%) 15 (20.8%)
Stage III 79 (56.4%) 69 (50.7%) 38 (52.8%)
Stage IV 38 (27.1%) 31 (22.8%) 19 (26.4%)
Therapy [N (%)]    
Adjuvant 96 (68.6%) 96 (70.6%) 47 (65.3%)
Metastatic 44 (31.4%) 40 (29.4%) 25 (34.7%)
Prior radiation therapy [N (%)]    
No 125 (89.3%) 127 (93.4%) 63 (87.5%)
Yes 15 (10.7%) 9 (6.6%) 9 (12.5%)
  1. Abbreviations: SD = Standard deviation,
  2. Body Mass Index calculated as body weight/(height)2
  3. *Patients in this group received placebo in cycle 1 and XM02 afterwards